Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2024 09:31 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the...
March 12, 2024 09:20 ET | Source: Celularity Inc.

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies...
March 12, 2024 09:15 ET | Source: Artelo Biosciences

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
March 12, 2024 09:00 ET | Source: T2 Biosystems, Inc.

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
March 12, 2024 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in 36th Annual ROTH Conference

MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
March 12, 2024 08:30 ET | Source: Tenax Therapeutics

Tenax Therapeutics to Present at the 36th Annual Roth Conference

CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and...
March 12, 2024 08:01 ET | Source: Mainz BioMed NV

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
March 12, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...
March 12, 2024 08:00 ET | Source: Spectral AI, Inc.

Spectral AI Announces New US Government Contract to Further Accelerate the Development of the Handheld Version of DeepView™ Wound Imaging System

DALLAS, March 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and...
March 12, 2024 08:00 ET | Source: electroCore, Inc.

electroCore to Participate in Upcoming Investor Conferences

ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Strategy...